Osborn Williams & Donohoe’s Supernus Pharmaceuticals SUPN Stock Holding History

Osborn Williams & Donohoe’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8,000	Closed	-$220K	–	312
2019 Q3	$220K	Hold	8,000	–	–	0.02%	296
2019 Q2	$265K	Hold	8,000	–	–	0.03%	285
2019 Q1	$306K	Hold	8,000	–	–	0.03%	294
2018 Q4	$266K	Hold	8,000	–	–	0.05%	194
2018 Q3	$403K	Hold	8,000	–	–	0.06%	184
2018 Q2	$479K	Hold	8,000	–	–	0.08%	163
2018 Q1	$366K	Hold	8,000	–	–	0.06%	175
2017 Q4	$319K	Sell	8,000 -1,000	-11%	-$39.5K	0.05%	188
2017 Q3	$360K	Hold	9,000	–	–	0.06%	175
2017 Q2	$388K	Hold	9,000	–	–	0.07%	169
2017 Q1	$282K	Hold	9,000	–	–	0.05%	188
2016 Q4	$227K	Hold	9,000	–	–	0.04%	200
2016 Q3	$223K	Buy	+9,000	New	+$204K	0.04%	204

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osborn Williams & Donohoe's SUPN Position: Q4 2019 in Review

Osborn Williams & Donohoe sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 8,000 shares — an estimated $220K sold.

Osborn Williams & Donohoe first reported a position in SUPN in Q3 2016 and held it in 13 quarters. The position peaked at $479K in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

Osborn Williams & Donohoe reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Osborn Williams & Donohoe sold 8,000 Supernus Pharmaceuticals shares in Q4 2019, an estimated $220K.
Osborn Williams & Donohoe first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 13 quarters.
Osborn Williams & Donohoe's Supernus Pharmaceuticals position peaked at $479K in Q2 2018.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q4 2019, filed 2 Mar 2020.